Site Editor

Thomas Flaig, MD

Advertisement

Advertisement

JNCCN Spotlights

Enfortumab Vedotin-ejfv

Medical Literature

Can Treatment-Specific COXEN Scores Predict Responses to Neoadjuvant Chemotherapy for Bladder Cancer?

News

Priority Review Accepted by FDA for Nivolumab in Adjuvant Treatment of Muscle-Invasive Urothelial Cancer

News

First-Line Treatments in Metastatic Urothelial Cancer: Real-World Decision-Making

Medical Literature

Does Use of Aspirin Improve Outcomes in Older Adults With Bladder Cancer?

News

Priority Review Accepted by FDA for Nivolumab in Adjuvant Treatment of Muscle-Invasive Urothelial Cancer

Medical Literature

TP53-Mutated Bladder Cancer: Identifying Patients Who May Benefit From Immunotherapy

Syed A. Hussain, MD, on Neoadjuvant Treatment With Nintedanib for Locally Advanced Disease

Tracy L. Rose, MD, on Clinical Implications of Treating Bladder Cancer With Neoadjuvant Gemcitabine, Cisplatin, and Pembrolizumab

View More

Advertisement

JNCCN Spotlights

Enfortumab Vedotin-ejfv

View More

More

News

Chronic Kidney Disease: Risk Factor for Muscle-Invasive Bladder Cancer?

Two sBLAs Accepted by FDA for Enfortumab Vedotin-ejfv in Urothelial Cancer

Long-Term Outcomes and Costs of BCG Therapy for High-Risk Non–Muscle-Invasive Bladder Cancer

Adjuvant Durvalumab for Localized Urothelial Cancer

Priority Review Accepted by FDA for Nivolumab in Adjuvant Treatment of Muscle-Invasive Urothelial Cancer

Neoadjuvant Cabazitaxel Plus Cisplatin in Muscle-Invasive Bladder Cancer

GU Symposium 2021: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Cancer

Enfortumab Vedotin-ejfv: Antibody-Drug Conjugate for Advanced Urothelial Carcinoma

View More

Advertisement

Published

Medical Literature

Combination Regimen Under Study in Metastatic Urothelial Carcinoma

Update on Managing Non–Muscle-Invasive Bladder Cancer

Can Leukocyte Telomere Length Predict Bladder Cancer Risk?

Bladder Urothelial Carcinoma: Is Age Related to Risk of Lymph Node Metastasis?

View More

Ongoing

CE Activities

New Therapeutic Developments In Urothelial Cancer: Clinical Trial Evidence And Expert Guidance

Advances in Treatment of Urothelial Carcinoma

Metastatic Urothelial Carcinoma: 2020 Multidisciplinary Molecular Tumor Board

Current and Emerging Treatment Options for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Carcinoma)

View More

Available

Clinical Trials

Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

View More

Resources

For Your Patients

Bladder Cancer Advocacy Network

American Cancer Society

American Bladder Cancer Society

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.